Thoughtful selection and use of scientific terms in clinical research: the case of 'pragmatic' trials

被引:8
|
作者
Dal-Re, Rafael [1 ]
Mentz, Robert J. [2 ,3 ]
Rosendaal, Frits R. [4 ]
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst, Epidemiol Unit, Madrid, Spain
[2] Duke Univ, Med Ctr, Div Cardiol, Duke Clin Res Inst, Durham, NC USA
[3] Duke Univ, Med Ctr, Dept Cardiol, Div Cardiol, Durham, NC USA
[4] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
关键词
biomedical research; drugs; investigational; education; medical; GENERALIZABILITY; ATTITUDES;
D O I
10.1136/jim-2021-001789
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical research is a discipline prone to the use of technical terms that may be particularly at risk for misunderstanding given the complex interpretation that is required. In this century, what is happening with the word 'pragmatic' when describing a randomized controlled trial (RCT) with medicines deserves a public reflection. Explanatory trials are conducted in ideal conditions to assess the comparative efficacy of interventions and are useful to explain whether interventions work. Pragmatic trials are those conducted in a way that resembles usual clinical practice conditions to assess the comparative effectiveness of interventions in a manner directly applicable for decision-makers. This, however, did not prevent 36% of authors of placebo-controlled, or prelicensing trials to identify their medicines RCTs as pragmatic in the title of their articles. The current situation is such that scientific literature has accepted that 'pragmatic' can convey the original meaning-that obtained in trials mimicking usual clinical practice-and a distorted one-that is focused on streamlining any trial procedure. Those involved in clinical trials should emphasize the importance of precision in the use of terms when describing RCTs through standardized solutions when possible. Unless clinical trial stakeholders agree when it would be correct to label an RCT as pragmatic, in a short period of time the term will be in danger of becoming meaningless. It is suggested that the Enhancing the Quality and Transparency of Health Research (EQUATOR) network, the Consolidated Standards of Reporting Trials (CONSORT) group and the International Committee of Medical Journal Editors (ICMJE) could address this topic and provide a consensus way forward.
引用
收藏
页码:1056 / 1058
页数:3
相关论文
共 50 条
  • [31] A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials
    Chen, Stephanie C.
    Kim, Scott Y. H.
    CLINICAL TRIALS, 2016, 13 (06) : 605 - 611
  • [32] THE RELATIONSHIP BETWEEN SCIENTIFIC RESEARCH, CLINICAL TRIALS AND FDA DRUG APROVAL
    Burgon, J.
    Hamerslag, L.
    VALUE IN HEALTH, 2013, 16 (07) : A478 - A478
  • [34] Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement
    Hohenschurz-Schmidt, David J.
    Cherkin, Dan
    Rice, Andrew S. C.
    Dworkin, Robert H.
    Turk, Dennis C.
    McDermott, Michael P.
    Bair, Matthew J.
    DeBar, Lynn L.
    Edwards, Robert R.
    Farrar, John T.
    Kerns, Robert D.
    Markman, John D.
    Rowbotham, Michael C.
    Sherman, Karen J.
    Wasan, Ajay D.
    Cowan, Penney
    Desjardins, Paul
    Ferguson, McKenzie
    Freeman, Roy
    Gewandter, Jennifer S.
    Gilron, Ian
    Grol-Prokopczyk, Hanna
    Hertz, Sharon H.
    Iyengar, Smriti
    Kamp, Cornelia
    Karp, Barbara I.
    Kleykamp, Bethea A.
    Loeser, John D.
    Mackey, Sean
    Malamut, Richard
    McNicol, Ewan
    Patel, Kushang V.
    Sandbrink, Friedhelm
    Schmader, Kenneth
    Simon, Lee
    Steiner, Deborah J.
    Veasley, Christin
    Vollert, Jan
    PAIN, 2023, 164 (07) : 1457 - 1472
  • [35] SCIENTIFIC AND ETHICAL ISSUES IN THE USE OF PLACEBO CONTROLS IN CLINICAL-TRIALS
    CLARK, PI
    LEAVERTON, PE
    ANNUAL REVIEW OF PUBLIC HEALTH, 1994, 15 : 19 - 38
  • [36] Scientific and ethical issues in the use of placebo and active controls in clinical trials
    Ellenberg, SS
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) : 1121 - 1124
  • [37] Assessing Longitudinal Medication Use in Pragmatic Clinical Trials: Insights From the ARTEMIS Trial
    Wang, Tracy
    Kaltenbach, Lisa A.
    Fonarow, Gregg C.
    Henry, Timothy D.
    Cannon, Christopher P.
    Cohen, David J.
    Fonseca, Eileen
    Bhandary, Durgesh D.
    Khan, Naeem
    Anstrom, Kevin J.
    Peterson, Eric D.
    CIRCULATION, 2017, 136
  • [38] USE OF A CLINICAL-TRIALS POPULATION IN GENETIC RESEARCH
    CHAN, P
    SHULTS, CW
    TANNER, CM
    FINK, JS
    KURTH, M
    MAREK, KL
    ELMER, LW
    AMERICAN JOURNAL OF HUMAN GENETICS, 1995, 57 (04) : 1835 - 1835
  • [40] The ethical and scientific case for phase 2C clinical trials
    Zee, Ying-Kiat
    Chan, Sarah W.
    Harris, John
    Jayson, Gordon C.
    LANCET ONCOLOGY, 2010, 11 (05): : 410 - 411